IP Library Granted Patent US 9,579,401
Granted Patent B2
US 9,579,401 · App. 13/638,105 · Granted Feb 28, 2017

Staining composition

Inventor: Gerrit Reinold Jacob Melles (Rotterdam, NL)
Assignee: Medical Technology Transfer Holding B.V.
A61K49/001A61K49/003A61K49/006A61K49/0023A61K49/0028A61K49/0034A61K49/0071A61K9/0048
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,579,401
App. No.
13/638,105
Granted
Feb 28, 2017
Kind
B2
Abstract

The invention is directed to a staining composition and to the use of the staining composition in staining ocular tissue. In a first aspect, the invention provides a staining composition comprising a vital dye and a density increasing compound chosen from the group consisting of water soluble polymers and small inert molecules.

Claims (31)

1. A method of treatment comprising,

staining an ocular tissue or part of an ocular tissue with a staining composition,

wherein the staining composition comprises a first and a second dye,

wherein the first dye is trypan blue (TB) and the second dye is brilliant blue G (BBG), and

wherein a concentration of polyethylene glycol in the staining composition is 2-10 wt. %.

2. The method according to claim 1 , wherein the staining composition further comprises a density increasing compound and wherein the density increasing compound is an iodinated organic compound.

3. The method according to claim 1 , wherein the polyethylene glycol has a molecular weight of 50-500,000 g/mol.

4. The method according to claim 1 , wherein the weight ratio of the first dye to the second dye in the dye of the staining composition is between 1:1 and 100:1.

5. The method according to claim 1 , wherein the staining composition further comprises a salt, wherein the salt is sodium chloride, potassium chloride, calcium chloride, magnesium chloride, or a combination thereof.

6. The method according to claim 1 , wherein the staining composition is an aqueous solution, a colloidal dispersion or a viscous or viscoelastomeric solution, and wherein the concentration of the in the staining composition is 2-10 wt. %.

7. The method according to claim 4 , wherein the staining composition has a density at 298 K of more than 1003 and less than 1040 kg*m −3 .

8. The method according to claim 4 , wherein the staining composition has a viscosity of at least 2.0 mPa·s, as determined using a rheometer at 298 K.

9. The method according to claim 1 , wherein the concentration of the first dye in the staining composition is 0.001-2 wt. %.

10. A method for preparing a staining composition, comprising the step of dissolving a first dye and a second dye,

wherein the first dye is trypan blue (TB) and the second dye is brilliant blue G (BBG), and

polyethylene glycol in a liquid; and dissolving a salt in the liquid to adjust the osmolarity of the liquid to a value between 250 and 400 mosmol/L.

11. The method according to claim 1 , wherein the treatment is part of an eye surgery.

12. The method according to claim 2 , wherein the density increasing compound is an iodixanol.

13. The method according to claim 2 , wherein the density increasing compound is 5-N(N-2,3-dihydroxypropylacetamido)-2,4,6-tri-iodo-N,N′-bis(2,3-dihydroxypropyl) isophtalamide.

14. The method according to claim 1 , wherein the polyethylene glycol has a molecular weight of 300-100,000 g/mol.

15. The method according to claim 1 , wherein the polyethylene glycol has a molecular weight of 600-40,000 g/mol.

16. The method according to claim 1 , wherein the weight ratio of the first dye to the second dye in the dye of the staining composition is between 2:1 and 25:1.

17. The method according to claim 1 , wherein the weight ratio of the first dye to the second dye in the dye of the staining composition is between 4:1 and 15:1.

18. The method according to claim 1 , wherein the staining composition is an aqueous solution, a colloidal dispersion or a viscous or viscoelastomeric solution, wherein the concentration of the polyethylene glycol in the staining composition is 3-6 wt. %.

19. The method according to claim 4 , wherein the staining composition has a density at 298 K of more than 1004-1026 kg·m −3 .

20. The method according to claim 4 , wherein the staining composition has a viscosity of at least 2.2 mPa·s, as determined using a rheometer at 298 K.

21. The method according to claim 4 , wherein the staining composition has a viscosity of at least 2.5 mPa·s, as determined using a rheometer at 298 K.

22. The method according to claim 1 , wherein the concentration of the first dye in the staining composition is 0.01-1 wt. %.

23. The method according to claim 1 , wherein the concentration of the first dye in the staining composition is 0.1-0.5 wt. %.

24. The method according to claim 1 , wherein the treatment is part of a vitreo-retinal surgery.

25. The method according to claim 1 , wherein the treatment is part of a capsulorhexis procedure.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 28, 2018
From: FENELON HOLLAND HOLDING B.V.
To: D.O.R.C. DUTCH OPHTHALMIC RESEARCH CENTER (INTERNATIONAL) B.V.
Reel/Frame 045372/0149 →
CHANGE OF NAME Recorded Mar 22, 2018
From: MEDICAL TECHNOLOGY TRANSFER HOLDING B. V.
To: FENELON HOLLAND HOLDING B.V.
Reel/Frame 045311/0206 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2012
From: MELLES, GERRIT REINOLD JACOB
To: MEDICAL TECHNOLOGY TRANSFER HOLDING B. V.
Reel/Frame 029253/0975 →
Priority Claims (2)
EP 10159021 · Apr 1, 2010 · regional
EP 10164866 · Jun 3, 2010 · regional
Continuity (1)
Related Publication 20130045167A1 · Feb 21, 2013